Patrick G Morris

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Breast Cancer 10:33-9. 2010
  2. pmc Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer
    Patrick G Morris
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 E 66th St, New York, NY 10065, USA
    Cancer Prev Res (Phila) 6:428-36. 2013
  3. doi request reprint Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Oral Maxillofac Surg 70:2768-75. 2012
  4. doi request reprint Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:5454-62. 2012
  5. doi request reprint Limited overall survival in patients with brain metastases from triple negative breast cancer
    Patrick G Morris
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Breast J 18:345-50. 2012
  6. doi request reprint Bevacizumab is an active agent for recurrent high-grade glioma, but do we need randomized controlled trials?
    Patrick G Morris
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Anticancer Drugs 23:579-83. 2012
  7. doi request reprint Advances in therapy: eribulin improves survival for metastatic breast cancer
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Evelyn H Lauder Breast Center, New York, USA
    Anticancer Drugs 21:885-9. 2010
  8. doi request reprint Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas
    Patrick G Morris
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Target Oncol 5:193-200. 2010
  9. doi request reprint Bone scans, bisphosphonates, and a lack of acute changes within the mandible
    Patrick G Morris
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Oral Maxillofac Surg 69:114-9. 2011
  10. doi request reprint Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib
    Patrick G Morris
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Cancer Res 17:3490-9. 2011

Detail Information

Publications35

  1. doi request reprint Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Breast Cancer 10:33-9. 2010
    ..A prospective clinical study was designed to explore this hypothesis. Patients and..
  2. pmc Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer
    Patrick G Morris
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 E 66th St, New York, NY 10065, USA
    Cancer Prev Res (Phila) 6:428-36. 2013
    ....
  3. doi request reprint Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Oral Maxillofac Surg 70:2768-75. 2012
    ..We investigated N-telopeptide of type I collagen (NTX) and bone-specific alkaline phosphatase (BAP) as potential predictors of ONJ onset...
  4. doi request reprint Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:5454-62. 2012
    ....
  5. doi request reprint Limited overall survival in patients with brain metastases from triple negative breast cancer
    Patrick G Morris
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Breast J 18:345-50. 2012
    ..This single-institution, retrospective study confirms that the prognosis for patients with BMs from TNBC remains poor. This group of patients urgently needs improved therapies...
  6. doi request reprint Bevacizumab is an active agent for recurrent high-grade glioma, but do we need randomized controlled trials?
    Patrick G Morris
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Anticancer Drugs 23:579-83. 2012
    ..7-11.2), in agreement with other series. In this editorial, the context and implications of these results are discussed, with a particular focus on the possible need and design of randomized phase III trials...
  7. doi request reprint Advances in therapy: eribulin improves survival for metastatic breast cancer
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Evelyn H Lauder Breast Center, New York, USA
    Anticancer Drugs 21:885-9. 2010
    ..Future studies will investigate the potential role of eribulin in other settings, including for early breast cancer, to ascertain how to optimally incorporate this new agent into current treatment paradigms...
  8. doi request reprint Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas
    Patrick G Morris
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Target Oncol 5:193-200. 2010
    ..This review describes the preclinical science behind PDGFR and c-KIT, the clinical importance of these molecular pathways and the available data from translational clinical trials...
  9. doi request reprint Bone scans, bisphosphonates, and a lack of acute changes within the mandible
    Patrick G Morris
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Oral Maxillofac Surg 69:114-9. 2011
    ..We examined this association within a prospective study assessing the effect of IVBPs on radionuclide bone scanning...
  10. doi request reprint Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib
    Patrick G Morris
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Cancer Res 17:3490-9. 2011
    ....
  11. ncbi request reprint Dose-dense chemotherapy for breast cancer: what does the future hold?
    Patrick G Morris
    Evelyn H Lauder Breast Center, 300 E 66th St, New York, NY 10065, USA
    Future Oncol 6:951-65. 2010
    ..Newer targeted agents may be similarly incorporated into dose-dense regimens to further improve patient outcomes. This article reviews dose-dense therapy and discusses its role as a chemotherapy foundation for additional targeted agents...
  12. pmc Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer
    Patrick G Morris
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 28:3154-9. 2010
    ..In this retrospective, single-institution study, we compare the diagnostic performance of integrated positron emission tomography/computed tomography (PET/CT) and bone scintigraphy (BSc) in women with suspected MBC...
  13. pmc Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction
    Patrick G Morris
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 27:6117-23. 2009
    ..Dose-dense (dd) AC followed by paclitaxel (P) is superior to the same regimen given every third week. Herein, we report the early cardiac safety of three sequential studies of ddAC alone or with bevacizumab (B)...
  14. doi request reprint Personalizing therapy for metastatic breast cancer
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Expert Rev Anticancer Ther 9:1223-6. 2009
    ..This article covers key new areas of systemic therapy for MBC from the American Society of Clinical Oncology 2009 annual meeting...
  15. doi request reprint Microtubule active agents: beyond the taxane frontier
    Patrick G Morris
    Memorial Sloan Kettering Cancer Center, Breast Cancer Medicine Service, New York, New York 10021, USA
    Clin Cancer Res 14:7167-72. 2008
    ..A variety of other agents that act on the microtubules at different sites with a variety of structures are at varying stages of development...
  16. ncbi request reprint Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer 119:3943-51. 2013
    ..The incidence of congestive heart failure (CHF) at a median follow-up of 2 years was 1.4% and 3.2%, respectively...
  17. pmc A CXCL1 paracrine network links cancer chemoresistance and metastasis
    Swarnali Acharyya
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cell 150:165-78. 2012
    ..This network of endothelial-carcinoma-myeloid signaling interactions provides a mechanism linking chemoresistance and metastasis, with opportunities for intervention...
  18. doi request reprint Novel anti-tubulin cytotoxic agents for breast cancer
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Expert Rev Anticancer Ther 9:175-85. 2009
    ..Elucidating the relative importance of these agents and incorporating them into existing treatment paradigms is a significant challenge for the future...
  19. doi request reprint Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 117:5461-8. 2011
    ..Therefore, a retrospective, single-institution, sequential cohort study of women with small, node-negative, HER2+ breast cancer who did or did not receive adjuvant trastuzumab was conducted...
  20. ncbi request reprint Therapeutic options for metastatic breast cancer
    Patrick G Morris
    Memorial Sloan Kettering Cancer Center, Breast Cancer Medicine Service, NY 10065, New York, USA
    Expert Opin Pharmacother 10:967-81. 2009
    ..We hope that further progress elucidating the pathophysiology and biology of MBC will continue to lead to corresponding advances in treatment...
  21. pmc Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer
    Gary A Ulaner
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York Department of Radiology, Weill Cornell Medical College, New York, New York
    Cancer Med 2:725-33. 2013
    ..SUVmax and TLG were both predictors of survival in breast cancer patients with bone metastases. TLG may be a more informative biomarker of OS than SUVmax for patients with LN and liver metastases. ..
  22. pmc Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women
    Kotha Subbaramaiah
    Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA
    Cancer Discov 2:356-65. 2012
    ..These findings help to explain the link among obesity, low-grade chronic inflammation, and breast cancer with important clinical implications...
  23. doi request reprint Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer
    Ana P Kiess
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:1982-8. 2012
    ..In this sequential, retrospective study, the authors evaluated whether adjuvant trastuzumab was associated with reduced LRR in women with lymph node-negative, HER2-positive disease who received breast-conservation therapy (BCT)...
  24. doi request reprint Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy
    Patrick G Morris
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 7:382-5. 2012
    ..A retrospective review was carried out to assess the impact of whole brain radiotherapy (WBRT), intrathecal therapy (IT), and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) on outcomes...
  25. pmc Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue
    Neil M Iyengar
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer 120:983-91. 2014
    ..Although obesity increases risk and negatively affects survival for many malignancies, the prognostic implications in squamous cell carcinoma (SCC) of the oral tongue, a disease often associated with prediagnosis weight loss, are unknown...
  26. pmc Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer
    Volkan Beylergil
    aDepartment of Radiology, Molecular Imaging and Therapy Service bDepartment of Medicine, Breast Cancer Medicine Service cHuman Oncology and Pathogenesis Program dDepartment of Medical Physics eRadiochemistry and Molecular Imaging Probes Core Facility, Memorial Sloan Kettering Cancer Center Departments of fRadiology gMedicine, Weill Cornell Medical College, New York, New York, USA
    Nucl Med Commun 34:1157-65. 2013
    ....
  27. pmc Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer
    Patrick G Morris
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer Prev Res (Phila) 4:1021-9. 2011
    ..The presence of CLS-B may be a biomarker of increased breast cancer risk or poor prognosis...
  28. doi request reprint Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy
    Patrick G Morris
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 52:1891-7. 2011
    ..51). Similarly, there were no differences in response rates or overall survival according to MTX AUC, suggesting that intra-patient dose escalation to increase MTX exposure is unnecessary when our regimen is utilized...
  29. ncbi request reprint Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Adv Hematol Oncol 7:115-22. 2009
    ..Further clinical studies assessing the role of ixabepilone in other settings, as well as the clinical investigation of other epothilones, are eagerly awaited...
  30. doi request reprint Translating mathematical modeling of tumor growth patterns into novel therapeutic approaches for breast cancer
    Elizabeth Comen
    Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill College of Medicine of Cornell University, New York, NY 10021, USA
    J Mammary Gland Biol Neoplasia 17:241-9. 2012
    ....
  31. doi request reprint Recent advances in novel targeted therapies for HER2-positive breast cancer
    Conleth G Murphy
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Anticancer Drugs 23:765-76. 2012
    ..In this review, recent data on these emerging agents and novel combinations for HER2-positive breast cancer are discussed...
  32. doi request reprint Optimizing the use of anthracyclines in older patients with breast cancer
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 475 New York NY 10065, USA
    Crit Rev Oncol Hematol 77:131-41. 2011
    ..This review will focus on the benefits and risks of anthracyclines in older patients with various subtypes of breast cancer...
  33. pmc Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs
    Thordur Oskarsson
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Med 17:867-74. 2011
    ..These findings link TNC to pathways that support the fitness of metastasis-initiating breast cancer cells and highlight the relevance of TNC as an extracellular matrix component of the metastatic niche...
  34. doi request reprint Therapeutic challenges in primary CNS lymphoma
    Patrick G Morris
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Lancet Neurol 8:581-92. 2009
    ..A promising area of research is the incorporation of novel targeted drugs into standard treatment frameworks. In the future, greater cooperation between research groups should hopefully lead to further therapeutic advances...
  35. pmc Aromatase inhibitor strategies in metastatic breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Womens Health 1:67-72. 2010
    ..It is hoped that these therapeutic innovations will lead to ongoing improvements in quality of life parameters and ideally survival for women with hormone-sensitive MBC...